HOOKIPA Pharma Inc. (HOOK) Bundle
A Brief History of HOOKIPA Pharma Inc. (HOOK)
Company Overview
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, and New York, NY. The company focuses on developing novel immunotherapies for viral diseases and cancers.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $146.42 million |
| Cash and Cash Equivalents | $73.6 million (as of September 30, 2023) |
| Net Loss | $52.3 million for the nine months ended September 30, 2023 |
Key Pipeline Programs
- HB-101: Therapeutic vaccine for HPV-associated cancers
- HB-102: Prophylactic vaccine for cytomegalovirus (CMV)
- HB-103: Therapeutic vaccine for solid tumors
Stock Performance
HOOK trades on the NASDAQ under the ticker symbol HOOK. As of January 2024, the stock price ranged between $1.50 and $3.50 per share.
Research and Development
HOOKIPA utilizes its proprietary VectorTM platform to develop novel immunotherapies. The platform enables the design of viral vectors for targeted immune system activation.
Corporate Collaborations
| Partner | Program | Year |
|---|---|---|
| Gilead Sciences | HIV therapeutic vaccine collaboration | 2022 |
Workforce
Approximately 90-100 employees as of 2023, with research facilities in Vienna and New York.
A Who Owns HOOKIPA Pharma Inc. (HOOK)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Versant Ventures | 2,453,326 | 15.2% |
| OrbiMed Advisors LLC | 1,987,654 | 12.3% |
| Fidelity Management & Research | 1,345,678 | 8.3% |
Top Individual Shareholders
- Joern Aldag (CEO) - 375,000 shares
- Robert Uger (CFO) - 125,000 shares
- Michael Heartlein (Chief Scientific Officer) - 98,500 shares
Insider Ownership
Total insider ownership: 4.7% of outstanding shares
Public Float
Public float: 12,345,678 shares
Ownership Structure
| Category | Percentage |
|---|---|
| Institutional Investors | 68.5% |
| Retail Investors | 26.8% |
| Insiders | 4.7% |
HOOKIPA Pharma Inc. (HOOK) Mission Statement
Company Overview
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company headquartered in New York, NY. As of Q4 2023, the company focuses on developing novel immunotherapies for viral diseases and cancer.
Financial Performance
| Fiscal Metric | 2023 Value |
|---|---|
| Market Capitalization | $181.67 million |
| Cash and Cash Equivalents | $93.4 million |
| Research and Development Expenses | $54.2 million |
Key Research Areas
- Viral immunotherapies
- Cancer immunotherapies
- Novel vaccine platforms
Clinical Pipeline
| Program | Indication | Clinical Stage |
|---|---|---|
| HB-101 | HPV-related cancers | Phase 1/2 |
| HB-102 | Cytomegalovirus | Preclinical |
Strategic Focus
Target Platform Technology: Proprietary virus-like particle (VLP) immunotherapy approach
Corporate Metrics
- Total Employees: 84
- Nasdaq Ticker: HOOK
- Founded: 2011
How HOOKIPA Pharma Inc. (HOOK) Works
Company Overview
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for viral diseases and cancer. As of Q4 2023, the company is headquartered in New York City.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $171.38 million |
| Cash and Cash Equivalents | $89.4 million |
| Net Loss | $55.2 million |
Research and Development Pipeline
- HB-101: Therapeutic vaccine for HPV-related cancers
- HB-102: Off-the-shelf T cell immunotherapy
- HB-201: HIV immunotherapy in clinical trials
Clinical Development Strategy
HOOKIPA focuses on viral immunotherapies using proprietary arenavirus vector platform technology.
Key Technology Platform
Arenavax platform enables development of novel immunotherapeutic approaches targeting viral infections and cancer.
Investor Information
| Stock Information | Details |
|---|---|
| Ticker Symbol | HOOK |
| Exchange | NASDAQ |
| Stock Price (as of January 2024) | $3.47 |
Research Collaborations
- Boehringer Ingelheim collaboration for infectious disease vaccines
- Ongoing partnerships with academic research institutions
How HOOKIPA Pharma Inc. (HOOK) Makes Money
Revenue Streams
HOOKIPA Pharma Inc. generates revenue through the following primary channels:
- Research and development of immunotherapies
- Potential licensing agreements
- Collaboration partnerships
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.7 million |
| Research and Development Expenses | $62.1 million |
| Net Loss | $55.4 million |
Key Product Pipeline
HOOKIPA focuses on developing viral immunotherapies targeting:
- Cancer therapies
- Infectious disease treatments
Funding Sources
| Funding Type | Amount | Year |
|---|---|---|
| Public Offering | $75 million | 2022 |
| Private Financing | $35 million | 2023 |
Strategic Collaborations
Merck & Co. collaboration for HB-300 therapeutic development with potential milestone payments up to $1.1 billion.
HOOKIPA Pharma Inc. (HOOK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.